Skip to content

Trial · Interventional

CompletedPhase 2Registry data

Phase II Solar Urticaria (SU) Pilot Study

NCTNCT00859534 (opens ClinicalTrials.gov in a new tab)Other idCUV016
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
5 participants (actual)
Sponsor
Clinuvel Pharmaceuticals Limited · Industry
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

United Kingdom

Start
Dec 2008
Primary completion
Jun 2009
Completion
Jul 2009
First posted
11 Mar 2009 (estimated)
Last update posted
15 Sept 2009 (estimated)
Conditions
Solar Urticaria

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200820092010
  1. Ph 2

    Phase II Solar Urticaria (SU) Pilot Study

    NCT00859534

    Dec 2008 to Jul 2009

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Urticaria is one of the most common dermatological conditions with diverse clinical presentations and causes. Solar urticaria (SU) is a rare subset of physical urticaria, where symptoms are induced by direct exposure of the skin to sunlight. As little as 5 minutes of sun exposure can cause flares and whealing on exposed skin sites, accompanied by severe itching. The wavelengths of radiation causing the eruption (i.e. the action spectrum) are in the ultraviolet or visible light range. Initially described by Merklen in 1904, SU may have a very sudden and dramatic onset, and then rapidly disappear once the exposure ceases. A delayed form of SU has also been reported, although this is extremely rare. Information on the pathophysiology of SU is limited and symptoms are confined to areas of the body exposed to direct sunlight. The condition can be very distressing and severely impair the individual's ability to go outdoors and to tolerate indoor lighting. The standard therapy, i.e. oral antihistamines, is only partially effective and may provide little worthwhile relief of symptoms. This pilot study is proposed to evaluate implants containing 16mg CUV1647 as a prophylactic treatment for patients with SU. The effectiveness of CUV1647 will be assessed by determining the minimum urticarial dose before and after treatment.

Interventions

  • afamelanotideDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. To determine whether a CUV1647 (synthetic alpha-MSH analogue) bioresorbable implant can reduce the susceptibility of patients with Solar Urticaria to provocation with a standardized light source (measured as a change in minimum urticarial dose, (MUD)).

    Time frame · 60 days

Secondary outcomes(3)

  1. To evaluate the safety/tolerability of CUV1647 by measuring treatment-emergent adverse events.

    Time frame · 60 days

  2. To determine the effect of CUV1647 on melanin density at several specified body sites.

    Time frame · 60 days

  3. To evaluate a change in the MUD between Days 30 and 60.

    Time frame · 60 days

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 70 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Male or female subjects with a diagnosis of solar urticaria (confirmed by phototesting) of sufficient severity that they have requested treatment to alleviate symptoms. * React to provocation with a light source * Aged 18-70 years * Fitzpatrick Skin Type I- IV * Written informed consent prior to the performance of any study-specific procedure. Exclusion Criteria: * Allergy to CUV1647 or the polymer contained in the implant * Any co-existent photodermatosis such as polymorphic light eruption (PLE), discoid lupus erythematosus (DLE) or erythropoietic porphyria (EPP). * Personal history of melanoma, lentigo maligna or multiple (3 or more) dysplastic nevi. * Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions. * Diagnosed with HIV/AIDS or hepatitis. * Any evidence of organ dysfunction or deviation from normal the clinical or laboratory determinations judged to be clinically significant by the Investigator. * History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, respiratory, endocrine (including diabetes, Cushing's syndrome, Addison's disease, Peutz-Jeagher syndrome), neurological (including seizures), haematological (especially anaemia of less than 10 g/100 mL) or systemic disease judged to be clinically significant by the Investigator. * Acute history of drug or alcohol abuse (in the last 12 months). * Major medical or psychiatric illness. * Patient assessed as not suitable for the study in the opinion of the investigator (e.g. noncompliance history, allergic to local anaesthetics, faints when given injections or giving blood). * Female who is pregnant (confirmed by positive serum β-HCG pregnancy test prior to baseline) or lactating. * Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device). * Sexually active men with partners of child bearing potential not using barrier contraception during the trial and for a period of three months hereafter. * Participation in a clinical trial for an investigational agent within 30 days prior to the screening visit. * Any factors that may affect skin reflectance measurements.

PepBank is a research reference. Talk to a doctor before you use any peptide.